A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
A form of economic evaluation comparing the costs of alternative interventions that have equal effects.
In Health care, Cost-minimisation analysis (CMA) is an economic appraisal that determines the least costly alternative therapy after the proposed drug has been established to be no more detrimental than its main competitor(s) in terms of capability and toxicity.
See also:
Cost–benefit analysis
Cost-effective (healthcare economics)
Cost-effectiveness league table (healthcare economics)
Cost-effectiveness threshold (health economics)
Cost consequences analysis (CCA)
Health technology assessment/appraisal (HTA), Porter's 'Five Forces', Elective care, Phase III trials, Quality of life (QOL), NHS Executive, Phase IV trials, Ad impression , Cost per thousand (CPM), Advertising research, Preferred provider organisation (PPO), Brief summary, Association of the British Pharmaceutical Industry (ABPI), Cost-effectiveness (in media/advertising), Continuing professional development (CPD),
Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...